# What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide | This GLP What orforglipron is, what ATTAIN-1 found at 72 weeks in 3,127 adults, and why a small-molecule tablet is chemically different from oral semaglutide | plus its tolerability. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-is-orforglipron Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Weight change at 72 weeks, once-daily tablet · placebo · 2.1% · 6 mg · 7.5% · 12 mg · 8.4% · 36 mg · 11.2% · 3,127 patients with obesity and no diabetes. No injection. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Orforglipron is a small-molecule tablet, not a peptide — a different chemical class from every other drug covered here, which is why it needs no injection and no absorption enhancer. - Over 72 weeks in 3,127 adults with obesity and no diabetes, weight fell 11.2% on the 36 mg dose against 2.1% on placebo. - On that dose, 54.6% lost at least 10% of their weight, 36.0% at least 15% and 18.4% at least 20%. - Adverse events ended treatment for 5.3% to 10.3% of the drug groups against 2.7% on placebo. - No trial has compared it against an injected GLP-1, so any such comparison is an eyeball across two studies. Orforglipron is a once-daily tablet that acts on the GLP-1 receptor and is not a peptide. In a 72-week phase 3 trial of 3,127 adults with obesity, weight fell 11.2% on the 36 mg dose against 2.1% on placebo [\[1\]](https://thisglp.com/research/what-is-orforglipron#ref-1). Everything else in this library is a peptide, either injected or put into a tablet with an absorption enhancer to survive the stomach. Orforglipron is neither. Being a small molecule is a chemistry difference with practical consequences: no cold chain, no needle, and none of the food-timing rules the existing pill requires. That last one is covered in [what the pill actually does](https://thisglp.com/research/oral-semaglutide-what-the-pill-does). For the diabetes-specific results, see the [three phase 3 orforglipron trials in type 2 diabetes](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes), rather than assuming that weight-loss and glucose-control endpoints are interchangeable. ## What the trial did ATTAIN-1 was a phase 3, multinational, double-blind trial in adults who had obesity and did not have diabetes. Patients were randomized in a 3:3:3:4 ratio to once-daily orforglipron at 6 mg, 12 mg or 36 mg, or to placebo, alongside diet and activity advice, for 72 weeks. The primary endpoint was percent change in body weight at week 72, analyzed in the intention-to-treat population. ## What it found Among the 3,127 patients randomized, mean weight change at 72 weeks was −7.5% at 6 mg (95% CI −8.2 to −6.8). The 12 mg dose gave −8.4% (95% CI −9.1 to −7.7). The 36 mg dose gave −11.2% (95% CI −12.0 to −10.4). Placebo gave −2.1% (95% CI −2.8 to −1.4). The thresholds are the more legible version of the same result. On 36 mg, 54.6% of patients lost 10% or more of their body weight, 36.0% lost 15% or more and 18.4% lost 20% or more. The placebo figures were 12.9%, 5.9% and 2.8%. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved against placebo as well. The comparison this page will not make It is tempting to set −11.2% beside the number you remember from a semaglutide or tirzepatide trial and rank them. Don’t. Those trials enrolled different people under different protocols, and no study has yet randomized anyone between a small-molecule tablet and an injected peptide. What can be said is narrower and still useful. A daily tablet with no absorption enhancer produced a double-digit mean reduction over 72 weeks, in a trial of more than three thousand people. That is a real result about this drug, and the only kind this trial supports. ## How it sits beside the other pill The nearest comparison is oral semaglutide, and it is not a randomized one. At 25 mg over 64 weeks, oral semaglutide produced a mean weight reduction of 13.6% against 2.2% on placebo in adults with overweight or obesity [\[2\]](https://thisglp.com/research/what-is-orforglipron#ref-2). Different trial, different population, different duration. A network meta-analysis of drugs for overweight and obesity places the whole class rather than ranking these two [\[3\]](https://thisglp.com/research/what-is-orforglipron#ref-3). Its finding is that the agents taking off the most weight are also the ones people stop soonest. Orforglipron’s discontinuation figures below are the same trade in miniature. ## What it costs in tolerability Adverse events led to discontinuation in 5.3% to 10.3% of patients across the three orforglipron groups, against 2.7% on placebo. The most common were gastrointestinal and mostly mild to moderate — the same pattern the injected drugs produce, described in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The dose-response runs both ways: the arm that lost most weight was also the arm people left most often. ## Where a reader will meet it It is already being sold. Several storefronts tracked here list the branded tablet. It is usually routed through the manufacturer’s own pharmacy with a membership charged beside it, which makes the advertised medication figure only part of the bill. That structure is the subject of [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). The dose question applies here as much as anywhere. 36 mg is the dose that produced the headline, and a seller quoting a starter price is quoting a different rung. Which sellers publish the rungs at all is counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). ## Frequently asked How is orforglipron different from the semaglutide pill? It is a small molecule rather than a peptide, so it does not need an absorption enhancer or the food-timing rules that come with one. Chemically it is a different class of drug acting on the same receptor. How much weight did people lose? A mean of 11.2% at 72 weeks on the 36 mg dose against 2.1% on placebo. On that dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Is it better than an injection? Nobody knows. No trial has randomized patients between orforglipron and an injected GLP-1, so comparing numbers across separate trials compares populations as much as drugs. How many people stopped because of side effects? Between 5.3% and 10.3% across the three dose groups, against 2.7% on placebo, mostly for gastrointestinal effects that were mild to moderate. ## Sources 1. \[1\] Wharton S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment New England Journal of Medicine. [PMID 40960239](https://pubmed.ncbi.nlm.nih.gov/40960239/) 2. \[2\] Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) 3. \[3\] Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. [PMID 42419792](https://pubmed.ncbi.nlm.nih.gov/42419792/) ## Prescription access ### LillyDirect’s Foundayo pathway Understand the prescription requirements, pharmacy pathway and payment terms before arranging Foundayo treatment. [Read the LillyDirect review →](https://thisglp.com/reviews/lillydirect-foundayo) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)